These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 22409309)

  • 1. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
    Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
    J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.
    Yang R; Li J; Jin J; Huang M; Yu Z; Xu X; Zhang X; Hou M
    Br J Haematol; 2017 Jan; 176(1):101-110. PubMed ID: 27734464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
    Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
    J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
    N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag.
    Garnock-Jones KP; Keam SJ
    Drugs; 2009; 69(5):567-76. PubMed ID: 19368418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
    Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M
    J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
    Katsutani S; Tomiyama Y; Kimura A; Miyakawa Y; Okamoto S; Okoshi Y; Ninomiya H; Kosugi H; Ishii K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
    Int J Hematol; 2013 Sep; 98(3):323-30. PubMed ID: 23896965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
    Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
    Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB; Keating GM; Garnock-Jones KP
    Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
    Saleh MN; Bussel JB; Cheng G; Meyer O; Bailey CK; Arning M; Brainsky A;
    Blood; 2013 Jan; 121(3):537-45. PubMed ID: 23169778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
    Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
    Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M; Rubinstein PG; Aboulafia DM
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.
    Mei H; Liu X; Li Y; Zhou H; Feng Y; Gao G; Cheng P; Huang R; Yang L; Hu J; Hou M; Yao Y; Liu L; Wang Y; Wu D; Shen X; Jin J; Luo J; Zeng Y; Zhou X; Xia R; Jiang Z; Bai Y; Niu T; Yang R; Hu Y
    Ann Hematol; 2024 Jul; 103(7):2273-2281. PubMed ID: 38842566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.